The FDA is investigating "longitudinal stent deformation" in Boston Scientific's Ion and Promus stents, but maintains that the devices are safe if used as approved.

The FDA is investigating reports that the thinner design of next-generation drug-eluting stents, including Boston Scientific's (NYSE:BSX) Ion and Promus models, might be prone to deforming after implantation.
At least two studies and one case study presented at a recent cardiology conference reported incidents in which either a Boston Scientific Ion or Promus stent deformed after it was deployed inside a coronary artery.
A Delaware jury sides with Johnson & Johnson's DePuy-Synthes subsidiary in a patent spat over 3...
Results of pivotal study on Covidien subsidiary eV3's Pipeline cerebral aneurysm device, published in...
Delphi Ventures' John Maroney joins ForSight Vision5 as president, CEO & Director as the...
Echo Therapeutics initiates discussions with the FDA on the regulatory pathway for its Symphony non-...
Study results revealed in Europe this week cast doubt on the efficacy of renal denervation for...